Sardar Alamzaib, MD
Interventional Cardiology · Houston, TXNPI 1609220656
Payments from drug & device makers
What this record shows
This record is dominated by grants: $7,100 of the $9,908 with a category attached, or 71.7%. 16 manufacturers reported payments, led by Medtronic at 45.2% of the total. Reporting peaked in 2022 at $6,028 and has fallen 98.0% since, to $122 in 2025. That places this record below the midpoint for interventional cardiology clinicians in TX, where the typical reported total is $9,094.
Across 81 payments — averaging $122.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Abbott$2K
- Boston Scientific$2K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$294
- Biosense Webster, Inc.$293
- Shockwave Medical, Inc$286
- plus $685 from 10 others
What the payments were for
- Grants$7,10072%
- Food & beverage$2,65927%
- Education$1492%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 7 | $4,481 |
| Abbott | 5 | $2,321 |
| Boston Scientific | 14 | $1,547 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 17 | $294 |
| Biosense Webster, Inc. | 2 | $293 |
| Shockwave Medical, Inc | 3 | $286 |
| Novartis | 16 | $256 |
| Philips North America LLC | 1 | $109 |
| Johnson & Johnson | 6 | $94 |
| Abiomed | 2 | $66 |
| Amgen | 1 | $45 |
| Penumbra, Inc. | 2 | $37 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Chiesi USA, Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| AstraZeneca | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RESOLUTE ONYX$4,149
- GENERAL - STENTS$1,100
- Carto 3$293
- HawkOne$122
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$121
- 3F$112
- Diamondback Coronary$109
- (6575) Coronary Undivided$109
- AVEIR$105
How this compares
$9,908 in reported general payments places this provider in the 50th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $14,261 |
| Carvedilol | 14 | $134 |
| Lisinopril | 15 | $123 |
| Metoprolol Succinate | 11 | $103 |
| Atorvastatin Calcium | 11 | $88 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Houston
- Juan GranadaHouston$4.1M
- John IsaacHouston$1.8M
- Sanjay KunapuliHouston$267K
- Michele SartoriHouston$266K
- Abhijeet DhobleHouston$161K
- Amir KashaniHouston$148K
- Dhaval ParekhHouston$137K
- Neal KleimanHouston$118K
- Mehran MassumiHouston$114K
- Eduardo HernandezHouston$112K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.